Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
Jazz (JAZZ) International Revenue Performance Explored
10:31am, Monday, 06'th May 2024
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
12:31pm, Thursday, 02'nd May 2024
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:01pm, Wednesday, 01'st May 2024
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates a
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
04:10pm, Wednesday, 01'st May 2024
DUBLIN , May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wedne
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
04:05pm, Wednesday, 01'st May 2024
– 12% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 13% year-over-year –– Submitted zanidatamab BLA for 2L BTC
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
04:05pm, Wednesday, 24'th Apr 2024
Overall survival and additional long-term follow-up data from the Phase 2b HERIZON-BTC-01 trial in previously treated HER2-positive metastatic biliary tract cancer (BTC) to be presented at ASCO 2024 D
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:08am, Wednesday, 24'th Apr 2024
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Three no-brainer stocks to buy with $100
07:25am, Wednesday, 24'th Apr 2024
The stock market's strong performance in 2024 has made many investment options too expensive for some traders. However, with the recent pullback, an opportunity has emerged to invest in excellent valu
3 No-Brainer Stocks to Buy With $300 Right Now
05:21am, Wednesday, 24'th Apr 2024
Dips in the broader market have historically served as a buying opportunity for long-term-minded investors. A majority of online brokers have shelved commission fees and minimum deposit requirements i
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
04:15pm, Wednesday, 17'th Apr 2024
DUBLIN , April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
04:31am, Monday, 15'th Apr 2024
Jazz Pharmaceuticals is rated as a "Buy" due to its current financial health, multiple near-term catalysts, and projected growth for 2024 and 2025. The company's successful commercial products include
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
07:45am, Wednesday, 10'th Apr 2024
Two oral presentations share results of real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex® (cannabidiol) in treatment-resistant epilepsies Thirteen abstracts unde
Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanidatamab for previously treated HER2-positive biliary tract cancer (BTC) Confirmato
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
12:37pm, Friday, 29'th Mar 2024
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
02:25pm, Wednesday, 13'th Mar 2024
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno
